OncologyEducation presents MedOncNow
MedOncNow is a medical oncology podcast presented by OncologyEducation in partnership with Dr. Shaqil Kassam. Hosted by Dr. Kassam, the show explores hot topics in medical oncology, including emerging therapies and new standards of care. Each episode features discussions with leading oncology experts who share practical insights. The podcast aims to provide relevant information that listeners can incorporate into their clinical practice.
Episodes
A Waterfall of Options - Perioperative Bladder Cancer - Part 2
In this episode of MedOncNow, Dr. Aly-Khan Lalani, walks us through the rapidly evolving landscape of perioperative therapy for muscle-invasive bladder cancer — two practice-changing trials, two different patient populations, and a whole lot of practical decisions that no algorithm will make for you. This is particularly timely given there is an access program for this Regimen.
A Waterfall of Options - Perioperative Bladder Cancer - Part 1
In this episode of MedOncNow, Dr. Aly-Khan Lalani, walks us through the rapidly evolving landscape of perioperative therapy for muscle-invasive bladder cancer — two practice-changing trials, two different patient populations, and a whole lot of practical decisions that no algorithm will make for you. This is particularly timely given there is an access program for this Regimen.
Summiting Perioperative Gastric Cancer - With Dr. Howie Lim
In this episode, Dr. Howard Lim takes us through the peri-operative management of Gastric/GEJ Adenocarcinoma. This is particularly timely given Ontario now has funded access to the Matterhorn regimen, with the hopes of other provinces to follow.
Abema and Ribo - Adjuvant High Risk EBC with Dr. Aalok Kumar
In this episode, Dr. Aalok Kumar takes us through the practical aspects of choosing between the available adjuvant intensification options in "High Risk" HR+, HER2 - Early Breast Cancer. This is timely given there is public funding for Abemaciclib and PSP support for Ribociclib.
Targeted therapy in Cholangiocarcinoma - Part 2 - Ivosidenib
In this episode, Dr. Arndt Vogel takes us through targeted therapy in Biliary Tract Cancers. As we now have access to Pemigatinib (PART 1) to target FGFR2 fusions and Ivosidenib (PART 2) for IDH1 mutated cholangiocarcinoma, I thought it important to discuss how to incorporate these into practice.
Targeted therapy in Cholangiocarcinoma - Part 1 - Pemigatinib
In this episode, Dr. Arndt Vogel takes us through targeted therapy in Biliary Tract Cancers. As we now have access to Pemigatinib to target FGFR2 fusions and Ivosidenib for IDH1 mutated cholangiocarcinoma, I thought it important to discuss how to incorporate these into practice.
You Are What You Eat - Diet and Cancer with Dr. Urvi Shah
In this episode, Dr. Urvi Shah takes us through how to optimize diet in cancer treatment and prevention.
Targeting HER2 Alterations in NSCLC with Dr. Barbara Melosky
In this episode, Dr. Barb Melosky takes us through practical aspects of using HER2 targeted agents in HER2 altered advanced NSCLC. This is particularly timely given we now have access through company sponsored SAP programs for both Zongertinib and Sevabertinib.
Choosing in Advanced NSCLC - Without AGA, and EGFR+ with Dr. Natasha Leighl
In this episode, Dr. Natasha Leighl takes us through practical aspects of choosing treatments in advanced NSCLC without AGA and then in EGFR + NSCLC. We discuss treatments that are routinely available in clinic.
Sequencing in Advanced Colorectal Cancer - with Dr. Scott Berry
In this episode, Dr. Scott Berry takes us through practical discussions on sequencing the increasing available treatment options for Advanced Colorectal cancer.
BREAKWATER: Charting New Waters in Advanced BRAFmt CRC with Dr. Rachel Goodwin
As we now access Encorafenib + Cetuximab + Folfox via a Pfizer sponsored PSP for the he first line treatment Braf V600e mutated, RAS wt, dMMR/MSS metastatic Colorectal cancer, Dr. Rachel Goodwin takes us through the regimen, its practical use and efficacy and toxicity management.
Inavolisib in Endocrine Resistant PIK3CA Mutated HR+, HER2- Breast Cancer with Dr. Kasia Jerzak
As we now have access to Inavolisib via a ROCHE sponsored PSP for the first line treatment of endocrine resistant HR+ HER2- PIK3CA altered breast cancer progressing on or after adjuvant endocrine therapy, Dr. Kasia Jerzak takes us through the regimen, its practical use and efficacy and toxicity management.
TDXD a new DESTINY for HER2+ Gastro/GEJ adeno in 2nd line with Dr. Brezden-Masley
As we now have funded 2nd line access to TDXD (ENHERTU) in the treatment of HER2 + Gastric and GEJ cancer after Trastuzumab containing regimens, Dr. Christine Brezden-Masley takes us through the regimen, its use and efficacy and toxicity management
Check or Checkmate Ipi/Nivo in HCC with Dr. Hatim Karachiwala
In this episode of MedOncNow, Dr. Hatim Karachiwala discusses where IPI/NIVO is positioned in the first-line treatment options of advanced HCC. We discuss the regimen's efficacy with a focus on toxicity management. This is particularly timely as BMS has a compassionate access program for Ipilimumab and Nivolumab for advanced HCC.
IPI/NIVO for mCRC with Dr. Sharlene Gill
In this episode of MedOncNow, Dr. Sharlene Gill takes us through the evolving changes in the treatment of dMMR/MSI-H mCRC. Given that BMS has a company-sponsored PSP program, I felt it timely to discuss how Ipilimumab and Nivolumab fits into our treatment strategy.
The CHALLENGE to Move and Survive: Exercise After Adjuvant Colon Cancer Treatment with Dr. Christopher Booth
In this episode of MedOncNow, Dr. Christopher Booth discusses how 3 years of a structured exercise program after adjuvant chemotherapy for resected colon cancer can improve survival. This is an affordable, accessible and evidence-based strategy that can be incorporated into practice tomorrow.
Amivantamab + Lazertinib in 1st line Advanced EGFR + NSCLC - Mariposa
In this episode of MedOncNow, Dr. Kevin Jao discusses Amivantamab + Lazertinib in the first-line treatment of EGFR-mutated NSCLC and how it fits into the treatment landscape. This is timely, as Johnson & Johnson has a time-limited access program to Ami-Laz for EGFR-mutated NSCLC, as per the Mariposa Regimen. More information in episodes 2 and 3. Proudly partnering with Oncology Education for the
Claudin 18.2 - a SPOTLIGHT on Zolbetuximab - Part 2 of 2
In this episode of MedOncNow, Dr. Christine Brezden-Masley explores the clinical impact of Zolbetuximab in gastric and GEJ cancers, covering patient selection, treatment integration, and implications for systemic therapy delivery. This is timely as ASTELLAS is funding both testing for Claudin 18.2 and access to Zolbetuximab for Gastric and GEJ cancers across Canada. 🎧 Catch up on Part 1 for i
Claudin 18.2 - a GLOW-ing biomarker in Gastric Cancer - Part 1 of 2
In this episode of MedOncNow, Dr. Brandon Sheffield explores the role of Claudin 18.2 as a biomarker in gastroesophageal junction (GEJ) and gastric cancers. He discusses key considerations for testing and the evolving implications for biomarker-driven treatment in gastric cancer. This conversation is especially timely as ASTELLAS is currently funding Claudin 18.2 testing as part of the Gastric Can
Take 2 Aspirin and call me in the morning - Adjuvant therapy for Colorectal Cancer
Dr. Brandon Meyers joins Dr. Kassam to discuss the use of Adjuvant Aspirin in the management of curatively resected Colorectal Cancer in patients harbouring alterations in the PI3 Kinase pathway. This is a potentially practice-changing implementation of an affordable and tolerable drug that is easily accessible to patients.
Resectable NSCLC: How to Choose the Right Treatment
In episode 3 of MedOncNow, Dr. Parneet Cheema joins Dr. Kassam to discuss how to implement the multiple options available for treating resectable NSCLC. She will help us choose between CheckMate 816 and KEYNOTE-671 while also discussing CheckMate-77T, AEGEAN and IMpower010.
2L Treatment of EGFR-Positive NSCLC
Practically Speaking: Mariposa-2. In this episode of MedOncNow, Dr. Barb Melosky joins Dr. Kassam to discuss the use of Amivantimab + Carboplatin + Pemetrexed in the second-line treatment of EGFR-positive non small cell lung cancer (NSCLC) progressing after Osimertinib. A timely discussion, given that Johnson & Johnson now has a compassionate access program for this regimen.
Belzutifan - A Spark of Light for Clear Cell Renal Cell Carcinoma
Dr. Kassam is joined by Dr. Aly-Khan Lalani to discuss the use of Belzutifan in the management of previously treated clear cell renal cell carcinoma. With Belzutifan now available in clinic, listen today for important guidance.
Recommended
Separation Anxiety: The Alberta Referendum
Sufferless
Real Estate Investing Morning Show ( REI Investment in Canada )
Scott Fox After 9
Archives criminelles avec Daniel Renaud
UFO NEWS
Chez moi
Les filles du lunch
Academy of Ideas
Social Signalling Matters: An RO DBT Podcast
Aging Powerfully with Melissa Grelo
Awaken the Giant
